Companies · Biotechnology

Metagenomi Technologies, LLC

Emeryville · Biotechnology

Diligence memoA one-page analyst read on Metagenomi Technologies, LLC — recommendation, valuation, rhythm, risks.
$345.1M
Total raised · real
5
Rounds
0.5×
Latest step-up
Top 2%
Sector rank · raised
Series D+
Latest stage · inferred · Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Metagenomi Technologies, LLC looks fair against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.87× the median modeled value of Series D+ Biotechnology companies in 2022–2024 (75 peers) — value vs value, same stage and era.
  • Within the normal band (87% of peer median) for its niche.
At-risk
  • Last raise 3.5 yr ago; this sector typically re-raises about every 14 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Metagenomi Technologies, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
6.9 yr record
Peak capital year was 2022 with $271.2M across 2 filings.
Market position
ahead of 99% of Biotechnology peers
Capital scale is ahead of 99% of Biotechnology peers; modeled value is above 93% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2022: $271.2M across 2 filings.
  • Largest single filing was $175.4M on 2022-01-21.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Metagenomi Technologies, LLC is one of 4293 Biotechnology companies tracked from Emeryville. By capital raised it ranks among the largest (ahead of 99% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
25
Investors (latest)
2018
Year incorporated
2022-12-20
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3B$2.5B$3.8B$5.0BSeries B · 2019-08-02 Raised $26M (real) Modeled valuation $1.0B (est)$26M$1.0BSeries B2019Series B · 2020-11-10 Raised $38M (real) Modeled valuation $1.3B (est)$38M$1.3BSeries B2020Series B · 2021-03-15 Raised $10.0M (real) Modeled valuation $294M (est)$10.0M$294MSeries B2021Series D+ · 2022-01-21 Raised $175M (real) Modeled valuation $4.3B (est)$175M$4.3BSeries D+2022Series D+ · 2022-12-20 Raised $96M (real) Modeled valuation $1.7B (est)$96M$1.7BSeries D+2022+$38M+$10.0M+$175M+$96MCumulative $345M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$26.4M · 2019
Series B extension$37.5M · 2020
Series B extension$10.0M · 2021
Series D+$175.4M · 2022no Series C on file
Series D+ extension$95.8M · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A, Series C — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$1.7B
Base estimate est.
$434.3M
Conservative case
$2.9B
Upside case
$798.3M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series D+a $100M–$400M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series B · modeled $1.0B · 2019-08-022019Series B · modeled $1.3B · 2020-11-10Series B · modeled $293.6M · 2021-03-15Series D+ · modeled $4.3B · 2022-01-21Series D+ · modeled $1.7B · 2022-12-202022
Model inputs · modeled:benchmark-stage-stepup-v1
12%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
54% low · 75% high
1.39×/yr
Annual markup
1.56×/yr upside case
3.5 yr
Elapsed time used
3.5 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
10 mo
Avg between rounds
$102.0M/yr
Capital velocity
6.9 yr
On record since
2019
First round
5
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 48× above median
This company$345.1M
Sector median$7.2M
Latest round — vs other Series D+ rounds in sector (real $, this stage) 0.8× of median
This company$95.8M
Sector median$120.0M
Modeled value — vs sector median (estimate, all stages) 27× above median
This company$1.7B
Sector median$64.2M

Raised more than 99% of sector peers (real $). Modeled value above 93% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series D+) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #43 of 75.

This companyCohort peer
$1.0B$10.0B$100.0M$1.0BCapital raised (log)Areteia Therapeutics, Inc. · Series D+ Raised $360.0M · modeled $7.8B (est)GIO World Health Ltd · Series D+ Raised $300.0M · modeled $7.4B (est)Crinetics Pharmaceuticals, Inc. · Series D+ Raised $428.0M · modeled $4.3B (est)2seventy bio, Inc. · Series D+ Raised $170.0M · modeled $4.0B (est)Gio World Health (Europe) Sa · Series D+ Raised $150.0M · modeled $3.7B (est)GIO World Health (Europe) Ltd · Series D+ Raised $150.0M · modeled $3.7B (est)Arsenal Biosciences, Inc. · Series D+ Raised $579.2M · modeled $3.5B (est)ImmPACT Bio USA Inc. · Series D+ Raised $143.6M · modeled $3.5B (est)BioNTech SE · Series D+ Raised $400.0M · modeled $3.4B (est)RayzeBio, Inc. · Series D+ Raised $396.4M · modeled $3.4B (est)Genesis Therapeutics, Inc. · Series D+ Raised $297.4M · modeled $3.3B (est)Legend Biotech Corp · Series D+ Raised $350.5M · modeled $3.3B (est)Metagenomi Technologies, LLC (this company) Raised $345.1M · modeled $1.7B (est)Metagenomi Technologies, LLC
CompanyStageRaised · realValue · estvs peer med.
Areteia Therapeutics, Inc.Series D+$360.0M$7.8B3.87×
GIO World Health LtdSeries D+$300.0M$7.4B3.67×
Crinetics Pharmaceuticals, Inc.Series D+$428.0M$4.3B2.13×
2seventy bio, Inc.Series D+$170.0M$4.0B1.98×
Gio World Health (Europe) SaSeries D+$150.0M$3.7B1.84×
GIO World Health (Europe) LtdSeries D+$150.0M$3.7B1.84×
Arsenal Biosciences, Inc.Series D+$579.2M$3.5B1.76×
ImmPACT Bio USA Inc.Series D+$143.6M$3.5B1.72×
BioNTech SESeries D+$400.0M$3.4B1.71×
RayzeBio, Inc.Series D+$396.4M$3.4B1.69×
Genesis Therapeutics, Inc.Series D+$297.4M$3.3B1.64×
Legend Biotech CorpSeries D+$350.5M$3.3B1.63×
Metagenomi Technologies, LLC this companySeries D+$345.1M$1.7B0.87×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$26.4M2019-08-02$146.5M$1.0B90%
Series B$37.5M2020-11-10$208.6M$1.3B90%
Series B$10.0M2021-03-15$55.6M$293.6M90%
Series D+$175.4M2022-01-21$1.5B$4.3B90%
Series D+$95.8M2022-12-20$798.3M$1.7B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$26.4M2019-08-02
    • First recorded raise — entered as Series B.
    • 16 investors on this round.
  2. Series B$37.5M2020-11-10
    • Raised 15 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 11 investors on this round.
  3. Series B$10.0M2021-03-15
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 3.8× smaller than the prior — bridge or down round.
    • 2 investors on this round.
  4. Series D+$175.4M2022-01-21
    • Raised 10 mo later, in step with the ~14 mo sector norm.
    • Round 17.5× larger than the prior — scaling up.
    • 29 investors on this round.
  5. Series D+$95.8M2022-12-20
    • Raised 11 mo later, in step with the ~14 mo sector norm.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 25 investors on this round.
Intelligence
2023 ~Q4
Modeled next raise · ~10mo cadence
$95.8M
Modeled next size est.range $95.8M$153.3M
0.5×
Last step-up
$102.0M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
ANDREW LEVIN16 other2021-03
Risa Stack8 other2022-01
Brian Thomas4 other2019-08
Andrew Farquharson3 other2019-08
Jak Knowles3 other2019-08
Juergen Eckhardt2 other2020-11
Brian C. Thomas2022-12
Juergen C. Eckhardt2022-12
Risa C. Stack2022-12
Santhosh C. Palani2022-12
Santosh Palani2022-01
Sebastian Bernales2020-11
Sebastian C. Bernales2022-12
Willard C. Dere2022-12
Willard Dere2022-01
Registry & provenance

Metagenomi Technologies, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1785279
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Solstice Oncology, Inc.BiotechnologySeries D+$121.3M$774.4Mnetwork1 shared operator · same sector · same stage
Cytek BioSciences, Inc.BiotechnologySeries D+$120.0M$4.5Bnetwork1 shared operator · same sector · same stage
Neurona Therapeutics, IncBiotechnologySeries D+$347.5M$875.0Msame sector · same stage
Vir Biotechnology, Inc.BiotechnologySeries D+$348.4M$1.3Bsame sector · same stage
Sensei Biotherapeutics, Inc.BiotechnologySeries D+$348.9M$2.2Bsame sector · same stage
Carmot Therapeutics Inc.BiotechnologySeries D+$349.8M$2.4Bsame sector · same stage
Oric Pharmaceuticals, Inc.BiotechnologySeries D+$335.0M$1.0Bsame sector · same stage
MapLight Therapeutics, Inc.BiotechnologySeries D+$356.2M$1.5Bsame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
MetaBiotech CorpBiotechnologySeries A$331.8M93%
MetaStat, Inc.BiotechnologySeries A$122.2M88%
Biomimetics Innovations LtdBiotechnologyPre-Seed$799K88%
Metanoia Bio IncBiotechnologyPre-Seed$1.5M88%
CytoBioscience, Inc.BiotechnologySeries B$60.7M87%
Portal Biotechnologies, Inc.BiotechnologySeries A$49.5M87%
BiomeSense, Inc.BiotechnologySeries A$22.4M87%
BioRegenx Inc.BiotechnologyPre-Seed$2.1M87%
Frequently asked
How much funding has Metagenomi Technologies, LLC raised?
Metagenomi Technologies, LLC has raised approximately $345.1M in disclosed capital across 5 recorded financing rounds, aggregated from public filings.
What is Metagenomi Technologies, LLC's estimated valuation?
Provath's modeled valuation for Metagenomi Technologies, LLC is approximately $1.7B (modeled range $434.3M–$2.9B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Metagenomi Technologies, LLC at?
Metagenomi Technologies, LLC's latest modeled financing stage is Series D+. Its most recent recorded round closed around Tue Dec 20.
What does Metagenomi Technologies, LLC do and where is it based?
Metagenomi Technologies, LLC operates in the Biotechnology sector, based in Emeryville.
Explore related

See where Metagenomi Technologies, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Metagenomi Technologies, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.